CoChat
Sign Up
Cited by 37Hormonal and reproductive studiesNutrition and Health in AgingRegulation of Appetite and Obesity

The effects of testosterone on body composition in obese men are not sustained after cessation of testosterone treatment

Open access
Ng Tang Fui, Mark, Hoermann, Rudolf, Zajac, Jeffrey D., Grossmann, Mathis·2017·Clinical Endocrinology
DOI 10.1111/cen.13385
Open this paper in CoChat — free accountOpen PDF

Abstract

Summary: Background: Testosterone treatment in obese dieting men augments the diet‐associated loss of fat mass, but protects against loss of lean mass. We assessed whether body composition changes are maintained following withdrawal of testosterone treatment. Methods: We conducted a prespecified double‐blind randomized placebo‐controlled observational follow‐up study of a randomized controlled trial (RCT). Participants were men with baseline obesity (body mass index >30 kg/m 2) and a repeated total testosterone level <12 nmol/L, previously enrolled in a 56‐week testosterone treatment trial combined with a weight loss programme. Main outcome measures were mean adjusted differences (MAD) (95% confidence interval), in body composition between testosterone‐ and placebo‐treated men at the end of the observation period. Results: Of the 100 randomized men, 82 completed the RCT and 64 the subsequent observational study. Median [IQR] observation time after completion of the RCT was 82 weeks [74; 90] in men previously receiving testosterone (cases) and 81 weeks [67;91] in men previously receiving placebo (controls), P=.51. At the end of the RCT, while losing similar amounts of weight, cases had, compared to controls, lost more fat mass, MAD −2.9 kg (−5.7, −0.2), P=.04, but had lost less lean mass MAD 3.4 kg (1.3, 5.5), P=.002. At the end of the observation period, the former between‐group differences in fat mass, MAD −0.8 kg (−3.6, 2.0), P=1.0, in lean mass, MAD −1.3 kg (−3.0, 0.5), P=.39, and in appendicular lean mass, MAD −0.1 kg/m 2 (−0.3, 0.1), P=.45, were no longer apparent. During observation, cases lost more lean mass, MAD −3.7 kg (−5.5, −1.9), P=.0005, and appendicular lean mass, MAD −0.5 kg/m 2 (−0.8, −0.3), P<.0001 compared to controls. Conclusions: The favourable effects of testosterone on body composition in men subjected to a concomitant weight loss programme were not maintained at 82 weeks after testosterone treatment cessation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/cen.13385

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Increases in serum testosterone achieved by lifestyle changes are modest around 3 mM, and difficult to sustain.

    “In contrast, the increases in serum testosterone achieved by lifestyle changes are modest around 3 mM, 60 , 61 and difficult to sustain. 62”

    From The role of the androgen receptor in the pathogenesis of obesity and its utility as a target for obesity treatments (2022) · cites this paper as [62]

  • When re-evaluated 20 months after the end of the RCT, testosterone treatment effects on body composition were not sustained, and former between-group differences in fat and lean mass were no longer apparent.

    “When re-evaluated 20 months after the end of the RCT, 91,101 the testosterone treatment effects on body composition were not sustained, and the former between-group differences in fat and lean mass were no longer apparent.92”

    From Hypogonadism and male obesity: Focus on unresolved questions (2018) · cites this paper as [92]

  • Relatively short-term (56 weeks) testosterone treatment was not associated with a prolonged iatrogenic suppression of the HPT axis.

    “suggesting that relatively short-term (56 weeks) testosterone treatment was not associated with a prolonged iatrogenic suppression of the HPT axis.”

    From Hypogonadism and male obesity: Focus on unresolved questions (2018) · cites this paper as [92]

  • There were no differences in testosterone concentrations between previously testosterone- and placebo-treated men.

    “There were no differences in testosterone concentrations between previously testosteroneand placebo-treated men, 92”

    From Hypogonadism and male obesity: Focus on unresolved questions (2018) · cites this paper as [92]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Fui, M. N. T., Hoermann, R., Zajac, J. D. & Grossmann, M. (2017). The effects of testosterone on body composition in obese men are not sustained after cessation of testosterone treatment. CLINICAL ENDOCRINOLOGY, 87 (4), pp.336-343. https://doi.org/10.1111/ cen.13385. Persistent Link: http://hdl.handle.net/11343/293109

Cited by

Sorted by citations

Related

Authors
Ng Tang Fui, M., Hoermann, R., Zajac, J. D., & Grossmann, M.
Affiliations
  • Department of Medicine Austin Health University of Melbourne Heidelberg Vic. Australia
  • The University of Melbourne (AU)
Corresponding author
Grossmann, Mathis
ORCID
Venue
Clinical Endocrinology
Publisher
Wiley
Published
2017-06-27
Volume
87
Issue
4
Pages
336-343
ISSN
  • 0300-0664 (ISSN-L)
  • 1365-2265
DOI
10.1111/cen.13385
OpenAlex
W2616887830
Cited by
37
References
25
Citations by year
2026: 1 · 2025: 3 · 2023: 4 · 2022: 4 · 2021: 2 · 2020: 7 · 2019: 11 · 2018: 2 · 2017: 3
FWCI
4.97
Type
journal article
Language
en
Open access
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Clinical Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
  • Minerva Access (University of Melbourne) (submittedVersion)
Funders
  • National Health and Medical Research Council (1055305, 1024139)
  • Novartis
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
  • Health Sciences › Medicine › Physiology › Nutrition and Health in Aging
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
testosterone, obesity, body composition, fat mass, lean body mass, appendicular lean mass, weight loss, testosterone withdrawal, men
MeSH terms
Adult, Body Composition, Body Weight, Double-Blind Method, Female, Humans, Luteinizing Hormone, Male, Middle Aged, Obesity, Testosterone, Body Mass Index

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review